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Since the introduction of radionuclides into
clinical medicine, a number of specific tests have been
designed to test thyroid function and to diagnose diseases of the thyroid gland.
These studies can be broadly grouped into in
vivo and in vitro studies. Using 131 1 and 1251, tests have
been designed to measure thyroid function at the
hypothalamic, pituitary, or thyroid level and at the
peripheral level by radioimmunoassay or radioassay
of circulating thyroid hormones. The following
schema of testing may be used to assess thyroid function:
I. Hypothalamus. Following the intramuscular administration of thyrotropic-releasing hormone, the following
changes occur in plasma thyroid-stimulating hormone
(TSH) level, which can be measured by radioimmunoassay using '" I:
CONDITION
I. Normal
2. Hyperthyroidism
A. Toxic Diffuse Goiter
B. Toxic Nodular Goiter
C. Toxic Nodule
3. Hypothyroidism
A. Hypothalamic
B. Pituitary
C . Thyroid

TSH
Increased
No change
No change
No change
Increased
No change
Increased

II. Pituitary capability of secreting TSH under normal and
abnormal conditions can be accurately measured by determinati on of peripheral level of TSH using "'I radioimmunoassay techniques. The following are TSH values
for various thyroid disorders:
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TSH
1-lOµU / mlt

CONDITION
I. Normal
2. Hyperthyroidism
A. Toxic Diffuse Goiter
B. Toxic Nodular Goiter
C. Toxic Nodule
D. Hypothalamic
E. Pituitary Tumor
3. Hypothyroidism
A . Hypothalamic
B. Pituitary
C. Thyroid

Normal
Normal
Normal
Increased (I)
Increased (I)
Low
Normal
Increased

Ill. Assessment of thyroid glandular function can be determined by measuring the concentration of 131 I using basal
a nd dynamic studies fo llowing oral administration of "'I.
l. BASAL STUDIES

PERCENT
3 hours

131

1 CONCENTRATION

5 hours

24 hours

A. Normal Curve t2.5-l I.6% t4.l-14.9% t9.0-31.0%
B. Hyperthyroid
14.9%
31.0%
Curve
>11.6%
C. Hypothyroid
4.1%
9.0%
< 2.5
Curve
2. DYNAMIC STUDIES
A. TSH Stimulation Test
B. T-3 Suppression
C. KCIO, Discharge

NORMAL RESPONSE
> 50% Increase
> 50% Decrease
< 3% Decrease

Determination of the circulating thyroid hormones by radioassay and radioimmunoassay techniques using 125 1 are readily available and offer accurate measurement of these hormones when properly
performed. Normal values for the circulating hormones are as follows:
t Normal values for the Medical College of Virginia.
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l. Total thyroxine
2. Triiodothyronine
3. Serum free thyroxine

5.6-13.lµg / dlt
70-170 ng/ dlf
1.2-3.5 ng/ dlt

Discussion. Differential diagnosis of diseases of
the thyroid can be made with a high degree of certainty using the previously mentioned tests employing radionuclides. The clinical applicability of the
various tests is dependent upon a thorough knowledge of thyroid physiology and interrelationships of
trophic hormones and carrier proteins. A review of
the disease states and diagnosis using specific tests
follows.
l. Hyperthyroidism. The vast majority of cases
can be diagnosed on clinical grounds alone from the
history and physical findings . Confirmation is easily
obtained by employing the 1311 uptake at 3, 5, and 24
hours. This will be elevated in the majority of
hyperthyroid patients. The above-mentioned test in
conjunction with the T-4 and serum free thyroxine
(SFT)-4, which are usually elevated, will establish the
diagnosis in both Graves' disease and hyperthyroidism
due to a nodular goiter. If the diagnosis is suspected
on clinical grounds and the above tests are normal,
one can then perform the T-3 suppression study. This
is done by obtaining a baseline uptake at 3, 5, and 24
hours and then placing the patient on Ltriiodothyronine, I 50µg daily for seven days. The uptake in the normal person is suppressed after T-3 administration by at least 50% and is usually below 20%
at 24 hours. Hyperthyroid patients seldom suppress
below 20% and never below 50% of original uptake.
The usual hyperthyroid patient has little or no change
in 24-hour uptake following T-3. Data from our
laboratory on T-4 and SFT-4 also reveal less than
50% suppression in the hyperthyroid patient with the
average change being lµg/ dl or less. In rare cases,
thyrotoxicosis may be due to elevated T-3 levels.
Under these circumstances, the T-4 and SFT-4 and
uptake are normal but the latter is nonsuppressible.
2. Hypothyroidism. In contrast to hyperthyroidism, hypothyroidism is not always easy to diagnose.
This disease has protean manifestations and may be
insidious in onset.
Diagnosis when hypothyroidism is suspected
clinically is best confirmed by a 24-hour 1811 uptake of
less than 9% in 24 hours and a low total and free
thyroxine of less than 5.6µg / dl and 1.2 ng/ dl, respectively.
Differentiation between pituitary or thyroid
failure can now be made by measuring serum TSH by

125 1 radioimmunoassay following intramuscular or intravenous injection of thyrotropin-releasing hormone
(TRF). A rise in the serum TSH will occur within approximately 15 to 30 minutes after intravenous injection (2) and 2 to 3 hours after intramuscular TRF (3)
injection if the pituitary is intact. Failure to detect a
significant rise in TSH after TRF administration implies pituitary failure and hence, establishing the
diagnosis of secondary hypothyroidism.
3. Subacute thy roiditis. Diagnosis of subacute
thyroiditis is usually suggested by the clinical picture
of anterior neck pain with exacerbation on swallowing or coughing, radiation of pain to the ears,
hoarseness, and signs and symptoms of hypermetabolism. The thyroid is usually enlarged and especially
tender.
Laboratory confirmation is established by the
presence of a low 1811 uptake at 3, 5, and 24 hours and
an elevated T-4 and SFT-4.
4. Enzymatic defects. These are usually characterized by the presence of a goiter dating from early
childhood or the development of thyroid enlargement following ingestion of certain drugs or foods .
Laboratory studies usually demonstrate an
elevated 18 11 uptake value, low total T-4 and SFT-4
and discharge of 181 I from the thyroid gland of greater
than 3% following oral administration of potassium
perchlorate or potassium thiocyanate.
5. Nodules. Adequate assessment of both single
and multiple nodules in the thyroid gland require that
a scan be performed after the administration of 1311
(4), 125 1 (5) if available, or 99mTc (6). The former is
performed in our laboratory. Evaluation of nonfunctioning nodules subsequently removed surgically at
our institution over a ten-year period reveals that
single nonfunctioning nodules were malignant in
12.5% of cases, multiple nodules in 16.5%, with the
total overall incidence of malignancy being 13.0% in
nonfunctioning nodules. (These findings have been
noted in a study by J. M . Harrison, MD, R . H .
Kirkland, MD , and the author, unpublished data).
Or 24 malignant nodules out of 184 nonfunctioning nodules by scan.
The incidence of malignancy in hot nodules in
the same study was I out of 74, or 1.3%. Reexamination of the scan in the one case revealed that, in
retrospect, this most likely was a cold nodule. A
functioning nodule is thus strong evidence against
malignancy, although some reports of this occurring
have appeared in the literature (7).
The autonomous nodule with or without
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hyperthyroidism is characterized by uptake in the
nodule only and suppression of the remaining thyroid
tissue. The nodule fails to suppress following the administration of L-triiodothyronine as previously discussed and there is no significant change in the T-4 or
SFT-4 by 1251 radioassay. Thyroid-stimulating hormone and long-acting thyroid stimulator (LATS)
values are characteristically low for the former and
undetectable for the latter. Autonomy can be confirmed by repeating the scan after administration of
10 units of TSH.
Conclusion. Correct assessment of thyroid function and evaluation of nodules can be obtained by the
proper application of the appropriate in vivo or in
vitro tests as previously discussed. Thyroid function
can now be evaluated at the hypothalamic, pituitary,
and thyroid level using both 131 1 and 1251 and at the
peripheral level using 125 1 radioassay or radioimmunoassay procedures. Using these procedures as
described, quantitative evaluation of thyroid function
can be made, and in most instances the disease
process can be defined in a specific manner.
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